250 related articles for article (PubMed ID: 21872335)
1. The effect of aripiprazole and quinagolide, a dopamine agonist, in a patient with symptomatic pituitary prolactinoma and chronic psychosis.
Broekhof R; Gosselink MJ; Pijl H; Giltay EJ
Gen Hosp Psychiatry; 2012; 34(2):209.e1-3. PubMed ID: 21872335
[TBL] [Abstract][Full Text] [Related]
2. Aripiprazole reduces serum prolactin in a woman with prolactinoma and acute psychosis.
Sheldrick AJ; Gründer G
Pharmacopsychiatry; 2008 Jul; 41(4):160. PubMed ID: 18651348
[No Abstract] [Full Text] [Related]
3. Successful monotherapy treatment with aripiprazole in a patient with schizophrenia and prolactinoma.
Freeman B; Levy W; Gorman JM
J Psychiatr Pract; 2007 Mar; 13(2):120-4. PubMed ID: 17414690
[No Abstract] [Full Text] [Related]
4. Major depressive disorder induced by prolactinoma--a case report.
Liao WT; Bai YM
Gen Hosp Psychiatry; 2014; 36(1):125.e1-2. PubMed ID: 24182617
[TBL] [Abstract][Full Text] [Related]
5. Prolactin-secreting pituitary adenoma in neuroleptic treated patients with psychotic disorder.
Melkersson K; Hulting AL
Eur Arch Psychiatry Clin Neurosci; 2000; 250(1):6-10. PubMed ID: 10738858
[TBL] [Abstract][Full Text] [Related]
6. Evidence for the partial dopamine-receptor agonist aripiprazole as a first-line treatment of psychosis in patients with iatrogenic or tumorogenic hyperprolactinemia.
Hoffer ZS; Roth RL; Mathews M
Psychosomatics; 2009; 50(4):317-24. PubMed ID: 19687170
[TBL] [Abstract][Full Text] [Related]
7. Partial agonist properties of the antipsychotics SSR181507, aripiprazole and bifeprunox at dopamine D2 receptors: G protein activation and prolactin release.
Cosi C; Carilla-Durand E; Assié MB; Ormiere AM; Maraval M; Leduc N; Newman-Tancredi A
Eur J Pharmacol; 2006 Mar; 535(1-3):135-44. PubMed ID: 16554049
[TBL] [Abstract][Full Text] [Related]
8. Hormone levels and tumour size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically non-functioning pituitary adenomas: predictive value of pituitary scintigraphy with 123I-methoxybenzamide.
Colao A; Ferone D; Lastoria S; Cerbone G; Di Sarno A; Di Somma C; Lucci R; Lombardi G
Clin Endocrinol (Oxf); 2000 Apr; 52(4):437-45. PubMed ID: 10762286
[TBL] [Abstract][Full Text] [Related]
9. Normalization of prolactin with aripiprazole in a patient with psychotic depression and a comorbid pituitary microadenoma.
Steinhagen CK
Psychosomatics; 2007; 48(4):350-1. PubMed ID: 17600173
[No Abstract] [Full Text] [Related]
10. Hypogonadism due to hyperprolactinemia and subsequent first episode of psychosis.
Tsigkaropoulou E; Peppa M; Zompola C; Rizos E; Xelioti I; Chatziioannou S; Filippopoulou A; Lykouras L
Gend Med; 2012 Feb; 9(1):56-60. PubMed ID: 22333523
[TBL] [Abstract][Full Text] [Related]
11. Time course of the changes in antipsychotic-induced hyperprolactinemia following the switch to aripiprazole.
Lu ML; Shen WW; Chen CH
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Dec; 32(8):1978-81. PubMed ID: 18848860
[TBL] [Abstract][Full Text] [Related]
12. Aripiprazole in combination with other antipsychotic drugs may worsen psychosis.
Adan-Manes J; Garcia-Parajua P
J Clin Pharm Ther; 2009 Apr; 34(2):245-6. PubMed ID: 19250146
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of quinagolide in resistance to dopamine agonists: results of a multicenter study. Club de l'Hypophyse.
Rohmer V; Freneau E; Morange I; Simonetta C
Ann Endocrinol (Paris); 2000 Nov; 61(5):411-7. PubMed ID: 11084391
[TBL] [Abstract][Full Text] [Related]
14. The novel antipsychotic aripiprazole is a partial agonist at short and long isoforms of D2 receptors linked to the regulation of adenylyl cyclase activity and prolactin release.
Aihara K; Shimada J; Miwa T; Tottori K; Burris KD; Yocca FD; Horie M; Kikuchi T
Brain Res; 2004 Apr; 1003(1-2):9-17. PubMed ID: 15019558
[TBL] [Abstract][Full Text] [Related]
15. Surgery combined with dopamine agonists versus dopamine agonists alone in long-term treatment of macroprolactinoma: a retrospective study.
Höfle G; Gasser R; Mohsenipour I; Finkenstedt G
Exp Clin Endocrinol Diabetes; 1998; 106(3):211-6. PubMed ID: 9710362
[TBL] [Abstract][Full Text] [Related]
16. Hyperprolactinemia with aripiprazole: understanding the paradox.
Saraf G; Behere RV; Venkatasubramanian G; Rao NP; Varambally S; Gangadhar BN
Am J Ther; 2014; 21(3):e80-1. PubMed ID: 22357167
[TBL] [Abstract][Full Text] [Related]
17. Treatment of macroprolactinoma with the new potent non-ergot D2-dopamine agonist quinagolide and effects on prolactin levels, pituitary function, an the renin-aldosterone system. Results of a clinical long-term study.
Nickelsen T; Jungmann E; Althoff P; Schumm-Draeger PM; Usadel KH
Arzneimittelforschung; 1993 Apr; 43(4):421-5. PubMed ID: 8098604
[TBL] [Abstract][Full Text] [Related]
18. In vivo imaging of pituitary tumours using a radiolabelled dopamine D2 receptor radioligand.
de Herder WW; Reijs AE; Kwekkeboom DJ; Hofland LJ; Nobels FR; Oei HY; Krenning EP; Lamberts SW
Clin Endocrinol (Oxf); 1996 Dec; 45(6):755-67. PubMed ID: 9039343
[TBL] [Abstract][Full Text] [Related]
19. Treating prolactinoma and psychosis: medication and cognitive behavioural therapy.
Nieman DH; Sutterland AL; Otten J; Becker HE; Drent ML; van der Gaag M; Birchwood M; de Haan L
BMJ Case Rep; 2011 Feb; 2011():. PubMed ID: 22715200
[TBL] [Abstract][Full Text] [Related]
20. [Macroprolactinemia associated with pituitary macroadenoma: treatment with quinagolide].
Lakatos G; Szücs N; Kender Z; Czirják S; Rácz K
Orv Hetil; 2010 Jun; 151(26):1072-5. PubMed ID: 20558354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
